Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO) announced its quarterly earnings results on Thursday. The medical research company reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.44 by ($0.12), Bloomberg Earnings reports. The business had revenue of $624.43 million for the quarter, compared to analyst estimates of $636.50 million. Bio-Rad Laboratories had a net margin of 16.14% and a return on equity of 4.30%. Bio-Rad Laboratories updated its FY 2020
After-Hours guidance to EPS.

BIO stock traded up $24.29 during midday trading on Friday, reaching $403.63. 506,300 shares of the company’s stock traded hands, compared to its average volume of 168,406. The company has a market capitalization of $11.07 billion, a P/E ratio of 33.52, a PEG ratio of 2.77 and a beta of 1.16. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.72 and a quick ratio of 3.36. Bio-Rad Laboratories has a fifty-two week low of $262.38 and a fifty-two week high of $404.83. The business has a 50-day moving average price of $372.68 and a two-hundred day moving average price of $351.31.

A number of research analysts have weighed in on BIO shares. Citigroup started coverage on shares of Bio-Rad Laboratories in a research report on Monday, January 6th. They set a “buy” rating and a $450.00 price target on the stock. Wells Fargo & Co lifted their price target on shares of Bio-Rad Laboratories from $430.00 to $440.00 and gave the company an “overweight” rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $400.83.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Recommended Story: 52-Week Highs and Lows

Earnings History for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with's FREE daily email newsletter.